The Accelerated access review (AAR) was set up with the aim of speeding up access to innovative drugs, devices and diagnostics for NHS patients.  Following its report in 2016, the UK government has set up the Accelerated Access Pathway, a specialised system to streamline regulatory and market access decisions for ‘breakthrough’ products.  The Accelerated Access Collaborative (AAC) has been set up to identify and select innovative technologies and provide support and funding to enable them to achieve rapid adoption in the NHS.  The focus is on ‘affordable medicines or technologies which can dramatically improve efficiency, fill an unmet need or make a step-change in patient outcomes’.  So far, 12 ‘rapid uptake’ interventions in 7 technology areas (with ‘full evidence bases already within the system’) have been identified, of which 3 are medicines, 8 diagnostic tests and 1 a device.  In May 2019 it was announced that the role of the AAC will expand to become the new umbrella organisation for UK health innovation.

 

How to cite: Accelerated Access Review (UK) [online]. (2016). York; York Health Economics Consortium; 2016. https://yhec.co.uk/glossary/accelerated-access-review-uk/